English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 848209      Online Users : 867
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/4543


    Title: Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer
    Authors: Chen, YM;Wu, MF;Perng, RP;Chou, CM;Yang, KY;Lin, WC;Tsai, CM;Liu, JM;WhangPeng, J
    Contributors: National Institute of Cancer Research
    Abstract: We conducted a phase II study of ifosfamide and etoposide chemotherapy in patients with untreated extensive-disease small-cell lung cancer to assess response and toxicity, Between January 1994 and December 1995, 16 patients were treated, Ifosfamide and etoposide doses were ifosfamide 2 g/m(2), with mesna, i,v, infusion over 30 minutes on days 1-3 and etoposide 80 mg/m(2) i.v. over 120 minutes on days 1-3 every 4 weeks for up to six cycles, All patients were evaluable for toxicity profile and treatment response, As expected, the major toxicity was myelosuppression, With one exception, grade 3 or 4 leukopenia occurred in all patients during treatment, and 48.7% of the total courses had grade 3 or 4 leukopenia, Nine of 16 patients (56.3%) experienced episodes of febrile neutropenia, One toxic death due to febrile neutropenia with sepsis was documented, Toxicities other than leukopenia were few and mild in severity, After two cycles of treatment, the overall response rate was 81.3% (95% confidence interval 62.2-100) in this study, The median duration of response was 8 months and median survival was 11 months, In conclusion, ifosfamide and etoposide is an active combination regimen with acceptable toxicity profile in Chinese patients with extensive-disease small-cell lung cancer.
    Date: 1997-04
    Relation: Japanese Journal of Clinical Oncology. 1997 Apr;27(2):76-79.
    Link to: http://jjco.oxfordjournals.org/cgi/content/abstract/27/2/76
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0368-2811&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:A1997WX68200004
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0031110127
    Appears in Collections:[彭汪嘉康(1996-2007)] 期刊論文
    [劉敏(1996-2007)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    ISIA1997WX68200004.pdf49KbAdobe PDF919View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback